{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:24:58Z","timestamp":1772119498644,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10147-024-02504-4","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T23:50:51Z","timestamp":1713829851000},"page":"681-688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022"],"prefix":"10.1007","volume":"29","author":[{"given":"Tetsuhiro","family":"Yoshinami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamichi","family":"Yokoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Susumu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munetaka","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"2504_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq195","author":"J Crawford","year":"2010","unstructured":"Crawford J, Caserta C, Roila F et al (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdq195","journal-title":"Ann Oncol"},{"issue":"1","key":"2504_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 47(1):8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer."},{"issue":"28","key":"2504_CR3","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(28):3199\u20133212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"key":"2504_CR4","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Hematopoietic growth factors Version 2. 2023"},{"issue":"5","key":"2504_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","volume":"50","author":"BB Yang","year":"2011","unstructured":"Yang BB, Kido A (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 50(5):295\u2013306. https:\/\/doi.org\/10.2165\/11586040-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"2504_CR6","unstructured":"Morizane T, Yoshida M, Kojimahara N, et al (2014) Minds handbook for clinical practice guideline development 2014. Japan Council for Quality Health Care, Tokyo. https:\/\/minds.jcqhc.or.jp\/s\/developer_manual(in Japanese)"},{"key":"2504_CR7","unstructured":"Kojimahara N, Nakayama T, Morizane T, et al (2017) Minds manual for guideline development 2017. Japan Council for Quality Health Care, Tokyo"},{"issue":"1","key":"2504_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053252","volume":"8","author":"S Cesaro","year":"2013","unstructured":"Cesaro S, Nesi F, Tridello G et al (2013) A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. PLoS ONE 8(1):e53252. https:\/\/doi.org\/10.1371\/journal.pone.0053252","journal-title":"PLoS ONE"},{"issue":"6","key":"2504_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdf130","volume":"13","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, Jones SE, O\u2019Shaughnessy J et al (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13(6):903\u2013909. https:\/\/doi.org\/10.1093\/annonc\/mdf130","journal-title":"Ann Oncol"},{"issue":"3","key":"2504_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, O\u2019Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol 20(3):727\u2013731. https:\/\/doi.org\/10.1200\/JCO.2002.20.3.727","journal-title":"J Clin Oncol"},{"issue":"1","key":"2504_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14(1):29\u201335. https:\/\/doi.org\/10.1093\/annonc\/mdg019","journal-title":"Ann Oncol"},{"issue":"9","key":"2504_CR12","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/1042819031000103953","volume":"44","author":"A Grigg","year":"2003","unstructured":"Grigg A, Solal-Celigny P, Hoskin P et al (2003) Open-label, randomized study of pegfilgrastim vs daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 44(9):1503\u20131508. https:\/\/doi.org\/10.1080\/1042819031000103953","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2504_CR13","first-page":"715","volume":"10","author":"S Siena","year":"2003","unstructured":"Siena S, Piccart MJ, Holmes FA et al (2003) A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 10(3):715\u2013724","journal-title":"Oncol Rep"},{"issue":"3","key":"2504_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1200\/JCO.2003.03.040","volume":"21","author":"JM Vose","year":"2003","unstructured":"Vose JM, Crump M, Lazarus H et al (2003) Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21(3):514\u2013519. https:\/\/doi.org\/10.1200\/JCO.2003.03.040","journal-title":"J Clin Oncol"},{"issue":"8","key":"2504_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/1471-2407-8-195","volume":"10","author":"J Sierra","year":"2008","unstructured":"Sierra J, Szer J, Kassis J et al (2008) A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 10(8):195. https:\/\/doi.org\/10.1186\/1471-2407-8-195","journal-title":"BMC Cancer"},{"issue":"23","key":"2504_CR16","doi-asserted-by":"publisher","first-page":"7361","DOI":"10.1158\/1078-0432.CCR-09-0761","volume":"15","author":"E Fox","year":"2009","unstructured":"Fox E, Widemann BC, Hawkins DS et al (2009) Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin Cancer Res 15(23):7361\u20137367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0761","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2504_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3816\/CLML.2010.n.029","volume":"10","author":"R Rifkin","year":"2010","unstructured":"Rifkin R, Spitzer G, Orloff G et al (2010) Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 10(3):186\u2013191. https:\/\/doi.org\/10.3816\/CLML.2010.n.029","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2504_CR18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2009.24.8872","volume":"28","author":"SL Spunt","year":"2010","unstructured":"Spunt SL, Irving H, Frost J et al (2010) Phase II, randomized, open-label study of pegfilgrastim-supported VDC\/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol 28(8):1329\u20131336. https:\/\/doi.org\/10.1200\/JCO.2009.24.8872","journal-title":"J Clin Oncol"},{"issue":"5","key":"2504_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12032-015-0537-7","volume":"32","author":"W Zhang","year":"2015","unstructured":"Zhang W, Jiang Z, Wang L et al (2015) An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy. Med Oncol 32(5):147. https:\/\/doi.org\/10.1007\/s12032-015-0537-7","journal-title":"Med Oncol"},{"issue":"4","key":"2504_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/bjh.14088","volume":"174","author":"K Kubo","year":"2016","unstructured":"Kubo K, Miyazaki Y, Murayama T et al (2016) A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. Br J Haematol 174(4):563\u2013570. https:\/\/doi.org\/10.1111\/bjh.14088","journal-title":"Br J Haematol"},{"issue":"5","key":"2504_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/j.1600-0609.2006.00736.x","volume":"77","author":"M Martino","year":"2006","unstructured":"Martino M, Pratic\u00f2 G, Messina G et al (2006) Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 77(5):410\u2013415. https:\/\/doi.org\/10.1111\/j.1600-0609.2006.00736.x","journal-title":"Eur J Haematol"},{"issue":"2","key":"2504_CR22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00277-019-03901-w","volume":"99","author":"M Martino","year":"2020","unstructured":"Martino M, Gori M, Tripepi G et al (2020) A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant. Ann Hematol 99(2):331\u2013341. https:\/\/doi.org\/10.1007\/s00277-019-03901-w","journal-title":"Ann Hematol"},{"key":"2504_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.leukres.2019.05.006","volume":"82","author":"T Tadmor","year":"2019","unstructured":"Tadmor T, Levy I, Herishanu Y et al (2019) Primary peg-filgrastim prophylaxis versus filgrastim given \u201con demand\u201d for neutropenia during therapy with cladribine for hairy cell leukemia. Leuk Res 82:24\u201328. https:\/\/doi.org\/10.1016\/j.leukres.2019.05.006","journal-title":"Leuk Res"},{"issue":"7","key":"2504_CR24","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00520-014-2555-y","volume":"23","author":"G Kourlaba","year":"2015","unstructured":"Kourlaba G, Dimopoulos MA, Pectasides D et al (2015) Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer 23(7):2045\u20132051. https:\/\/doi.org\/10.1007\/s00520-014-2555-y","journal-title":"Support Care Cancer"},{"issue":"3","key":"2504_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2354.2008.00959.x","volume":"18","author":"D Almenar","year":"2009","unstructured":"Almenar D, Mayans J, Juan O et al (2009) Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain\u2013results of the LEARN Study. Eur J Cancer Care (Engl) 18(3):280\u2013286. https:\/\/doi.org\/10.1111\/j.1365-2354.2008.00959.x","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"9","key":"2504_CR26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/sj.bmt.1704927","volume":"35","author":"PB Staber","year":"2005","unstructured":"Staber PB, Holub R, Linkesch W et al (2005) Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 35(9):889\u2013893. https:\/\/doi.org\/10.1038\/sj.bmt.1704927","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2504_CR27","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.bbmt.2009.12.531","volume":"16","author":"A Gerds","year":"2010","unstructured":"Gerds A, Fox-Geiman M, Dawravoo K et al (2010) Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 16(5):678\u2013685. https:\/\/doi.org\/10.1016\/j.bbmt.2009.12.531","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2504_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3111\/13696998.2012.734885","volume":"16","author":"HJ Henk","year":"2013","unstructured":"Henk HJ, Becker L, Tan H et al (2013) Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. J Med Econ 16(1):160\u2013168. https:\/\/doi.org\/10.3111\/13696998.2012.734885","journal-title":"J Med Econ"},{"issue":"6","key":"2504_CR29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3816\/cbc.2003.n.003","volume":"3","author":"E Kubista","year":"2003","unstructured":"Kubista E, Glaspy J, Holmes FA et al (2003) Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 3(6):391\u2013398. https:\/\/doi.org\/10.3816\/cbc.2003.n.003","journal-title":"Clin Breast Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02504-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02504-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02504-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T04:24:41Z","timestamp":1716783881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02504-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2504"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02504-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3812794\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"3 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TE.Y. received honoraria from Kyowa-Kirin, Pfizer, Chugai, Eli Lilly, MSD, Astra Zeneca and Eisai. Y.O. received honoraria from Daiichi-Sankyo, Pfizer, Chugai, Lilly and Kyowa Kirin. K.T. received honoraria from Ono, Chugai, Taiho and Novartis. E.I. received honoraria from Eli Lilly, and research funding from MSD, Ono, Janssen Pharma and Takeda. Y.M. received honoraria from Ono, MSD, Takeda, Eisai and Bristol Myers Squibb, and research funding from MSD and Ono. S.Y. received research funding from Otsuka. D.M. received honoraria from Janssen, Nippon Shinyaku, Eisai, Mundipharma, Kyowa Kirin, Chugai, Zenyaku, MSD, SymBio, Sanofi, AbbVie, Takeda, Astra Zeneca and Bristol Myers Squibb, and research funding from Biopharma, Novartis, Kyowa Kirin, Ono, Chugai, Janssen, Takeda, Otsuka, Sanofi, Astellas, Bristol Myers Squibb, AbbVie, Eisai, MSD, Taiho and Astra Zeneca. T.M. received honoraria from Astra Zeneca, Chugai and Myriadgenetics. E.B. received honoraria from Chugai, and Daiichi-Sankyo, and research funding from Taiho and Chugai. T.KU. received honoraria from Chugai. T.KI. received honoraria from Sanofi. S.N. received honoraria from Kyowa Kirin. A.S. received honoraria and scholarship donation from Chugai and Taiho. T.T. received honoraria from Daiichi-Sankyo, Chugai and Eli Lilly. Other authors declare that there are no conflicts of interest associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Formal consent was not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consented to the publication of this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}